Inovio Pharmaceuticals Inc (INO)

[Scruffer]

BTW... 100% MR. It's shorts who get called.

Purchasing Inovio stock has a 100% "Margin Requirement" (MR) to buy this stock.

If one does not have the money in their account, simply, cannot purchase.

To the contrary, if "Short" the stock in the morning and goes up, then and only then will one get a margin call if do not have the funds to be 100% covered.

With 40,000 gentlemanly posts (and yes, you are a very polite poster), I would think you'd be aware of this.

Moreover, INO beats penny stock "Gambling". Also, caveat emptor implied on any stock.

Some good basic info about INO.

• https://www.inovio.com/
• https://www.inovio.com/about-inovio/mission-and-values/
• https://www.inovio.com/dna-medicines-pipeline/

• https://finance.yahoo.com/quote/INO/community?p=INO

• https://www.sec.gov/cgi-bin/browse-edgar?CIK=ino&owner=exclude&action=getcompany
• https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001055726&type=4&dateb=&owner=include&count=40

Nothing is proven by anyone so at this valuation, best play (for me--anyway).

All these vaccine approaches are pioneering technologies, unproven and the future:
• mRNA
• DNA
• Recombinant

Some company (hopefully) has to find a vaccine & win.

INO is one of the front-runners and "Leading" the DNA vaccine approach.

GLAL, Scruffer

P.S. Biotech stocks are essentially the most risky, but can be the most rewarding as well.

Any indication their DNA approach proves viable, this stock is going to triple digits ($15.81B+ valuation).

https://finance.yahoo.com/chart/INO#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%3D